Curation
Ncbi
Racine
Curation
Checkpoint
Ncbi
Racine
Ncbi
Exploration
Accueil
Racine
Racine

Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.

Identifieur interne : 000491 ( Ncbi/Curation ); précédent : 000490; suivant : 000492

Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.

Auteurs : Cindy Araya [Costa Rica] ; Bruno Lomonte

Source :

RBID : pubmed:17178238

Descripteurs français

English descriptors

Abstract

The effects of two cationic synthetic peptides, derived from the C-terminal region of Lys49 phospholipase A2 homologues from snake venoms, upon various murine tumor cell lines (B16 melanoma, EMT6 mammary carcinoma, S-180 sarcoma, P3X myeloma, tEnd endothelial cells) were evaluated. The peptides are 13-mers derived from Agkistrodon piscivorus piscivorus Lys49 PLA2 (p-AppK: KKYKAYFKLKCKK) and Bothrops asper Lys49 myotoxin II (pEM-2[D]: KKWRWWLKALAKK), respectively, in the latter case with slight modifications and with all-D amino acids. All tumor cells tested were susceptible to the lytic action of the peptides. The susceptibility of tumor cell lines was not higher than that of C2C12 skeletal muscle myoblasts, utilized as a non-transformed cell line control. However, in a murine model of subcutaneous solid tumor growth of EMT6 mammary carcinoma, the intraperitoneal administration of pEM-2[D] caused a tumor mass reduction of 36% (p<0.05), which was of similar magnitude to that achieved by the administration of paclitaxel, an antitumor drug in clinical use. Thus, the C-terminal peptides of Lys49 phospholipase A2 homologues present antitumor effects that might be of interest in developing therapeutic strategies against cancer.

DOI: 10.1016/j.cellbi.2006.11.007
PubMed: 17178238

Links toward previous steps (curation, corpus...)

Links to Exploration step

pubmed:17178238

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.</title>
<author>
<name sortKey="Araya, Cindy" sort="Araya, Cindy" uniqKey="Araya C" first="Cindy" last="Araya">Cindy Araya</name>
<affiliation wicri:level="1">
<nlm:affiliation>Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 2060, Costa Rica.</nlm:affiliation>
<country xml:lang="fr">Costa Rica</country>
<wicri:regionArea>Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 2060</wicri:regionArea>
<wicri:noRegion>San José 2060</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lomonte, Bruno" sort="Lomonte, Bruno" uniqKey="Lomonte B" first="Bruno" last="Lomonte">Bruno Lomonte</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17178238</idno>
<idno type="pmid">17178238</idno>
<idno type="doi">10.1016/j.cellbi.2006.11.007</idno>
<idno type="wicri:Area/PubMed/Corpus">002208</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002208</idno>
<idno type="wicri:Area/PubMed/Curation">002208</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002208</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002076</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002076</idno>
<idno type="wicri:Area/Ncbi/Merge">000491</idno>
<idno type="wicri:Area/Ncbi/Curation">000491</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.</title>
<author>
<name sortKey="Araya, Cindy" sort="Araya, Cindy" uniqKey="Araya C" first="Cindy" last="Araya">Cindy Araya</name>
<affiliation wicri:level="1">
<nlm:affiliation>Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 2060, Costa Rica.</nlm:affiliation>
<country xml:lang="fr">Costa Rica</country>
<wicri:regionArea>Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 2060</wicri:regionArea>
<wicri:noRegion>San José 2060</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lomonte, Bruno" sort="Lomonte, Bruno" uniqKey="Lomonte B" first="Bruno" last="Lomonte">Bruno Lomonte</name>
</author>
</analytic>
<series>
<title level="j">Cell biology international</title>
<idno type="ISSN">1065-6995</idno>
<imprint>
<date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Cell Death (drug effects)</term>
<term>Crotalid Venoms (chemistry)</term>
<term>Group II Phospholipases A2</term>
<term>Injections, Intraperitoneal</term>
<term>Mammary Neoplasms, Experimental (drug therapy)</term>
<term>Membranes (drug effects)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neoplasms, Experimental (drug therapy)</term>
<term>Neoplasms, Experimental (metabolism)</term>
<term>Neoplasms, Experimental (pathology)</term>
<term>Peptide Fragments (chemical synthesis)</term>
<term>Peptide Fragments (chemistry)</term>
<term>Peptide Fragments (pharmacology)</term>
<term>Phospholipases A (chemistry)</term>
<term>Phospholipases A2</term>
<term>Reptilian Proteins</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Cellules cancéreuses en culture</term>
<term>Fragments peptidiques ()</term>
<term>Fragments peptidiques (pharmacologie)</term>
<term>Fragments peptidiques (synthèse chimique)</term>
<term>Group II Phospholipases A2</term>
<term>Injections péritoneales</term>
<term>Membranes ()</term>
<term>Mort cellulaire ()</term>
<term>Phospholipases A ()</term>
<term>Phospholipases A2</term>
<term>Protéines de reptiles</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Séquence d'acides aminés</term>
<term>Tumeurs expérimentales (anatomopathologie)</term>
<term>Tumeurs expérimentales (métabolisme)</term>
<term>Tumeurs expérimentales (traitement médicamenteux)</term>
<term>Tumeurs expérimentales de la mamelle (traitement médicamenteux)</term>
<term>Venins de crotalidé ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en">
<term>Peptide Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Crotalid Venoms</term>
<term>Peptide Fragments</term>
<term>Phospholipases A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antineoplastic Agents</term>
<term>Peptide Fragments</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Tumeurs expérimentales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Cell Death</term>
<term>Membranes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Mammary Neoplasms, Experimental</term>
<term>Neoplasms, Experimental</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Neoplasms, Experimental</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Tumeurs expérimentales</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Neoplasms, Experimental</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antinéoplasiques</term>
<term>Fragments peptidiques</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr">
<term>Fragments peptidiques</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Tumeurs expérimentales</term>
<term>Tumeurs expérimentales de la mamelle</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Group II Phospholipases A2</term>
<term>Injections, Intraperitoneal</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Phospholipases A2</term>
<term>Reptilian Proteins</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Cellules cancéreuses en culture</term>
<term>Fragments peptidiques</term>
<term>Group II Phospholipases A2</term>
<term>Injections péritoneales</term>
<term>Membranes</term>
<term>Mort cellulaire</term>
<term>Phospholipases A</term>
<term>Phospholipases A2</term>
<term>Protéines de reptiles</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Séquence d'acides aminés</term>
<term>Venins de crotalidé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The effects of two cationic synthetic peptides, derived from the C-terminal region of Lys49 phospholipase A2 homologues from snake venoms, upon various murine tumor cell lines (B16 melanoma, EMT6 mammary carcinoma, S-180 sarcoma, P3X myeloma, tEnd endothelial cells) were evaluated. The peptides are 13-mers derived from Agkistrodon piscivorus piscivorus Lys49 PLA2 (p-AppK: KKYKAYFKLKCKK) and Bothrops asper Lys49 myotoxin II (pEM-2[D]: KKWRWWLKALAKK), respectively, in the latter case with slight modifications and with all-D amino acids. All tumor cells tested were susceptible to the lytic action of the peptides. The susceptibility of tumor cell lines was not higher than that of C2C12 skeletal muscle myoblasts, utilized as a non-transformed cell line control. However, in a murine model of subcutaneous solid tumor growth of EMT6 mammary carcinoma, the intraperitoneal administration of pEM-2[D] caused a tumor mass reduction of 36% (p<0.05), which was of similar magnitude to that achieved by the administration of paclitaxel, an antitumor drug in clinical use. Thus, the C-terminal peptides of Lys49 phospholipase A2 homologues present antitumor effects that might be of interest in developing therapeutic strategies against cancer.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000491 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000491 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:17178238
   |texte=   Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:17178238" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021